布格替尼在两项临床试验中对间变性淋巴瘤激酶阳性非小细胞肺癌伴脑转移患者的疗效探索性分析
在克唑替尼经治的ALK阳性非小细胞肺癌伴脑转移患者中,布格替尼(每日90至240 mg)在I/II期试验和随机II期ALTA试验中显示出颅内客观缓解率53%至67%,中位颅内无进展生存期在ALTA B组(180 mg每日一次,90 mg导入7天)达18.4个月。
要点
- 布格替尼在ALK阳性克唑替尼经治NSCLC伴脑转移患者中产生实质性颅内缓解。
- 可测量脑转移患者的确认颅内客观缓解率:I/II期53%、ALTA A组46%、B组67%。
- ALTA B组(180 mg每日一次,90 mg导入7天)中位颅内无进展生存期最长,为18.4个月。
核心结论
- 布格替尼在克唑替尼经治的ALK阳性非小细胞肺癌伴脑转移患者中产生实质性颅内缓解和持久的颅内无进展生存期,其中接受180 mg每日一次(含导入)的患者颅内无进展生存期最高。
研究设计与样本
- I/II期试验(NCT01449461)和随机II期ALTA试验(NCT02094573;A组90 mg每日一次,B组180 mg每日一次并7天90 mg导入)评估布格替尼(每日总剂量90至240 mg)。
- 独立评审委员会评估基线脑转移患者的颅内疗效。
主要发现
- 基线脑转移患者比例:I/II期50/79(63%),ALTA A组80/112(71%),B组73/110(66%)。
- 无既往脑放疗者比例:I/II期23/50(46%),ALTA A组32/80(40%),B组30/73(41%)。
- 可测量(≥10 mm)脑转移患者的确认颅内客观缓解率:I/II期53%(8/15;95% CI 27%至79%),ALTA A组46%(12/26;95% CI 27%至67%),B组67%(12/18;95% CI 41%至87%)。
- 无既往放疗或放疗后进展亚组的颅内客观缓解率相似。
- 任何基线脑转移患者的中位颅内无进展生存期:I/II期14.6个月(95% CI 12.7至36.8个月),ALTA A组15.6个月(95% CI 9.0至18.3个月),B组18.4个月(95% CI 12.8个月至未达到)。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Purpose In patients with crizotinib-treated, anaplastic lymphoma kinase gene ( ALK)-rearranged non-small-cell lung cancer (ALK-positive NSCLC), initial disease progression often occurs in the CNS. We evaluated brigatinib, a next-generation ALK inhibitor, in patients with ALK-positive NSCLC with brain metastases. Patients and Methods Patients with ALK-positive NSCLC received brigatinib (90 to 240 mg total daily) in a phase I/II trial (phI/II; ClinicalTrials.gov identifier: NCT01449461) and in the subsequent randomized phase II trial ALTA (ALK in Lung Cancer Trial of AP26113; ClinicalTrials.gov identifier: NCT02094573; patients in arm A received 90 mg once daily; patients in arm B received 180 mg once daily with 7-day lead-in at 90 mg). Primary end points (systemic objective response rates [ORRs]) were previously reported. Independent review committees assessed intracranial efficacy in patients with baseline brain metastases. Results Most patients with ALK-positive NSCLC had baseline brain metastases (50 of 79 [63%], phI/II; 80 of 112 [71%] and 73 of 110 [66%] in ALTA arms A and B, respectively), many of whom had no prior brain radiotherapy (23 of 50 [46%], phI/II; 32 of 80 [40%], ALTA arm A; 30 of 73 [41%], arm B). All patients, except four in phI/II, had received crizotinib. Among patients with measurable (≥ 10 mm) brain metastases, confirmed intracranial ORR was 53% (eight of 15; 95% CI, 27% to 79%) in phI/II, 46% (12 of 26; 95% CI, 27% to 67%) in ALTA arm A, and 67% (12 of 18; 95% CI, 41% to 87%) in arm B. Intracranial ORRs were similar in subsets without prior radiation or progression postradiation. Among patients with any baseline brain metastases, median intracranial progression-free survival (iPFS) was 14.6 months (95% CI, 12.7 to 36.8 months), phI/II; 15.6 months (95% CI, 9.0 to 18.3 months), ALTA arm A; 18.4 months (95% CI, 12.8 months to not reached), ALTA arm B. Conclusion Brigatinib yielded substantial intracranial responses and durable iPFS in ALK-positive, crizotinib-treated NSCLC, with highest iPFS in patients receiving 180 mg once daily (with lead-in).
引用
- Camidge DR, Kim DW, Tiseo M, et al. Exploratory Analysis of Brigatinib Activity in Patients With Anaplastic Lymphoma Kinase-Positive Non-Small-Cell Lung Cancer and Brain Metastases in Two Clinical Trials. J Clin Oncol. 2018. PMID: 29768119. doi:10.1200/JCO.2017.77.5841
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。